Answers are grounded in this paper and cite their sources.
Recombinant DNA technology has led to a significant increase in the number of peptide and protein based pharmaceuticals, giving a new approach to combat poorly controlled diseases. This particular development has been reached in the last two decades. However, proteins are highly susceptible of physical and chemical degradation resulting in a decrease or complete loss of biological activities. Reasons for their physical and chemical instabilities and the methods for their examination, become a challenge for the pharmaceutical scientists for successful development of stabile protein - based pharmaceuticals. The stability of protein - based pharmaceuticals is significant in terms of their pharmaceutical quality and biological activity. In addition, a right choice of suitable analytical methods is needed in order to detect an early formation of degradation products or modified forms.
No takes yet. Share an insight, caveat, or question.
Trajković-Jolevska et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: